foto

Prof. dr. H.N. Caron MD PhD

Position
Professor
Main activities
Research, Patient care
Specialisation
paediatric oncology
Focus of research

To improve the cure rates for children with cancer by developping new treatments and better risk stratification of current treatments and also to reduce side-effects for survivors of childhoodcancer by maximising the evidence-base for treatment decisions and guidelines for early detection and intervention.

Key publications
  • Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. NAT GENET 2012;44 (11):1199-1206 [PubMed]
  • Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GAM, van der Schoot CE, Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma. CLIN CANCER RES 2012;18 (3):808-814 [PubMed]
  • van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, Sieswerda E, Oldenburger F, Koning CC, van Leeuwen FE, Caron HN, Kremer LC, High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors. J CLIN ONCOL 2012;30 (13):1429-1437 [PubMed]
  • Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN, Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. P NATL ACAD SCI USA 2009;106 (31):12968-12973 [PubMed]
  • Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM, PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma. J CLIN ONCOL 2008;26 (33):5443-5449 [PubMed]
All Publications
Research programmes

Paediatric Oncology; biology and clinical

  1. Translational tumour biology (a.o. targetted drugs, MRD, tumor predisposition) (collaboration lab.Human Genetics, AMC)
  2. Clinical trials, incl. phase 1/2
  3. Evidence-base for Paediatric Oncology (a.o. Cochrane Childhood Cancer Systematic Review Group and guideline development)
  4. Long-term effects in survivors of paediatric cancer
  5. Psychosocial consequences of childhood cancer (PI = Dr.M.Grootenhuis, EKZ AMC)

Faculty
Prof. dr. H.N. Caron MD PhD
Dr. H. van den Berg MD PhD
Dr. C. van den Bos MD PhD
Dr. W.B. Breunis MD PhD
Prof. dr. M.A. Grootenhuis MSc PhD (Princess Maxima Center)
Dr. L.M. Haveman MD PhD
Dr. T. Israëls MD PhD
Prof. L.C.M. Kremer MD PhD
Dr. J.H.M. Merks MD PhD
Dr. A.Y.N. Schouten-van Meeteren MD PhD
Dr. G.A.M. Tytgat MD PhD
Dr. M.D. van de Wetering MD PhD
Dr. J. Zsiros MD PhD
Prof. C.M. Zwaan MD PhD

Postdocs
Dr. E.C. van Dalen MD PhD
Dr. J.J. Molenaar MD PhD

PhD Students
Drs. O.G. Besançon
A. Hakkert
Drs. J.L. Kok
A.M.J.B. Smets MD
Drs. N. Streefkerk MSc
Drs. J.C. Teepen MD (LUMC Leiden)
B. Vaarwerk
Drs. J. van Wijk
Drs. M.M. Geenen
Drs. J.H.C. Kok

Others
Dr. A.C. Verschuur MD PhD
Prof. dr. R. Versteeg

Other research related activities
  • Membership of medical or scientific committee, KWF Kankerbestrijding, Wetenschappelijke Raad
  • Membership of medical or scientific committee, KWF Kankerbestrijding, Beoordelingscommissie TTO
  • Membership of medical or scientific committee, University of Amsterdam, AMC Research Council
  • Membership of editorial board / Editorship, EUROPEAN JOURNAL OF CANCER
  • Membership of editorial board / Editorship, PEDIATRIC BLOOD & CANCER
  • Board of directors / Trustees / Supervisory board, Other
  • Membership of medical or scientific committee, DCOG (Dutch Childhood Oncology Group), LATER research group,
  • Membership of medical or scientific committee, DCOG (Dutch Childhood Oncology Group), New Agents Group
  • Contribution to guidelines and protocols, DCOG guidelines for longterm follow-up
  • Contribution to training of professionals, ASPO (Amsterdam School of Paediatric Oncology)
Current research funding
  • AMC
  • Institute Gustave Roussy